EPO and chronic kidney disease: Here, we demonstrate ex vivo in human small arteries from CKD patients a direct effect of EPO on endothelial function, which could participate in the increased blood pressure observed in CKD patients treated with EPO.5 The results of the present study may explain those of large clinical studies showing that for similar hematocrit levels, patients treated with EPO experience more CV events.